Suppr超能文献

用于评估候选尼帕疫苗中抗尼帕病毒中和活性的标准化假型病毒中和试验的开发与验证

Development and Validation of a Standardized Pseudotyped Virus-Based Neutralization Assay for Assessment of Anti-Nipah Virus Neutralizing Activity in Candidate Nipah Vaccines.

作者信息

Alam Muntasir, Rana Md Jowel, Salauddin Asma, Bentley Emma, Kamuyu Gathoni, Shill Dipok Kumer, Jahan Shafina, Alam Mohammad Mamun, Raihan Md Abu, Rahman Mohammed Ziaur, Raqib Rubhana, Azizi Ali, Rahman Mustafizur

机构信息

International Centre for Diarrheal Disease Research, Dhaka 1212, Bangladesh.

Department of Genomics and Bioinformatics, Chattogram Veterinary and Animal Sciences University, Chattogram 4202, Bangladesh.

出版信息

Vaccines (Basel). 2025 Jul 15;13(7):753. doi: 10.3390/vaccines13070753.

Abstract

An effective vaccine against Nipah virus (NiV) is crucial due to its high fatality rate and recurrent outbreaks in South and Southeast Asia. Vaccine development is challenged by the lack of validated accessible neutralization assays, as virus culture requires BSL-4 facilities, restricting implementation in resource-limited settings. To address this, we standardized and validated a pseudotyped virus neutralization assay (PNA) for assessing NiV-neutralizing antibodies in BSL-2 laboratories. The NiV-PNA was validated following international regulatory standards, using a replication-defective recombinant Vesicular stomatitis virus (rVSV) backbone dependent pseudotyped virus. Assessments included sensitivity, specificity, dilutional linearity, relative accuracy, precision, and robustness. The assay was calibrated using the WHO International Standard for anti-NiV antibodies and characterized reference sera to ensure reliable performance. Preliminary evaluation of the developed NiV-PNA showed 100% sensitivity and specificity across 10 serum samples (5 positive, 5 negative), with a positive correlation to a calibrated reference assay (R = 0.8461). Dilutional linearity (R = 0.9940) and accuracy (98.18%) were confirmed across the analytical titer range of 11-1728 IU/mL. The assay also exhibited high precision, with intra-assay and intermediate precision geometric coefficients of variation of 6.66% and 15.63%, respectively. Robustness testing demonstrated minimal variation across different pseudotyped virus lots, incubation times, and cell counts. : The validated NiV-PNA is a reproducible and scalable assay platform for quantifying NiV neutralizing antibodies, offering a safer alternative to virus culture. Its validation and integration into the CEPI Centralized Laboratory Network will enhance global capacity for vaccine evaluation and outbreak preparedness.

摘要

由于尼帕病毒(NiV)致死率高且在南亚和东南亚地区反复爆发,因此研发有效的疫苗至关重要。疫苗研发面临着缺乏经过验证的可及中和试验的挑战,因为病毒培养需要生物安全四级(BSL-4)设施,这限制了在资源有限环境中的实施。为解决这一问题,我们标准化并验证了一种假型病毒中和试验(PNA),用于在二级生物安全(BSL-2)实验室中评估抗NiV中和抗体。使用依赖复制缺陷型重组水疱性口炎病毒(rVSV)骨架的假型病毒,按照国际监管标准对NiV-PNA进行了验证。评估内容包括敏感性、特异性、稀释线性、相对准确性、精密度和稳健性。该试验使用世界卫生组织抗NiV抗体国际标准和特征明确的参考血清进行校准,以确保可靠的性能。对所开发的NiV-PNA的初步评估显示,在10份血清样本(5份阳性,5份阴性)中敏感性和特异性均为100%与校准后的参考试验呈正相关(R = 0.8461)。在11-1728 IU/mL的分析效价范围内,确认了稀释线性(R = 0.9940)和准确性(98.18%)。该试验还表现出高精密性,批内和中间精密度的几何变异系数分别为6.66%和15.63%。稳健性测试表明,在不同的假型病毒批次、孵育时间和细胞计数条件下,变异极小。经过验证的NiV-PNA是一种用于定量抗NiV中和抗体的可重复且可扩展的试验平台,为病毒培养提供了更安全的替代方法。其验证以及纳入流行病防范创新联盟(CEPI)中央实验室网络将提高全球疫苗评估能力和疫情防范能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c51f/12300343/67a74b725d14/vaccines-13-00753-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验